Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Trial Profile

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Condoliase (Primary)
  • Indications Intervertebral disc displacement
  • Focus Registrational; Therapeutic Use
  • Sponsors Seikagaku Corporation
  • Most Recent Events

    • 07 Nov 2017 Primary endpoint (Leg pain) has not been met, according to a Seikagaku Corporation media release.
    • 07 Nov 2017 According to a Seikagaku Corporation media release, status changed from active, no longer recruiting to completed.
    • 25 Nov 2015 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top